The Tissue Bank (Core C) provides the infrastructure to provide specimens from patients with myeloproliferative neoplasms (MPN) to investigators performing translational research for the purpose of developing innovative therapies for MPN pafients. The functions of the tissue bank are to: 1) acquire MPN tissues, 2) act as a repository for MPN tissues, 3) distribute MPN fissues for research, and 4) facilitate the performance of biomarker assays by distributing tissues to core laboratories. Tissues are available to members of the MPD Research Consortium (MPD-RC) and to the scientific community at large for the performance of translational research. Core C is an essential shared resource that enables translational research that will result in improved diagnosis and staging of MPN and ultimately lead to the development of molecularly targeted therapies.
The specific aims of Tissue Bank Core C are to: 1) Receive, process, cryopreserve, and store tissues from MPN patients diagnosed at MPD-RC clinical sites in an efficient, organized manner according to standard operafing procedures (SOPs). 2) Provide a central repository for MPN tissues that are associated with basic data stored in the web-based data bank maintained by Biostatistics and Data Management Core B. These basic data include clinical, laboratory and familial demographic data that enable selection and distribution of tissues best suited for each translational research project. 3) Make the cryopreseved tissues readily available to the MPD Consortium investigators and scientific community at large for research studies. 4) Facilitate the performance of biomarker assays designed to predict disease progression, thrombofic complications, and therapeutic response, by receiving, processing, cryopreserving, and storing tissues from MPN patients, and distributing these tissues to consortium biomarker assay labs. These tissues are collected from patients at diagnosis and at intervals designated in individual protocols described in Project 6. Biomarker assays provide data that are anticipated to correlate with clinical trial endpoints. Specimens from more than 600 patients are cun-ently banked in Core C. Tissues from more than 275 patients have been distributed for research to members of the MPD-RC and the scientific community at large.

Public Health Relevance

Translational research depends on the availability of specimens from pafients. MPNs are relatively uncommon resulting in a paucity of specimens available. Core C currently maintains one of the world's largest inventories of MPN specimens (from 600 patients) available for research by Consortium members and the scientific community at large. All patient samples are de-identified and electronically linked to clinical and demographic data to ensure accurate diagnosis and interpretation of data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA108671-07
Application #
8533757
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
7
Fiscal Year
2013
Total Cost
$781,394
Indirect Cost
$116,591
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Wang, Xiaoli; Cho, Sool Yeon; Hu, Cing Siang et al. (2015) C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. Exp Hematol 43:100-9.e1
Wehrle, Julius; Pahl, Heike L; von Bubnoff, Nikolas (2014) Ponatinib: a third-generation inhibitor for the treatment of CML. Recent Results Cancer Res 201:99-107
Spivak, Jerry L; Considine, Michael; Williams, Donna M et al. (2014) Two clinical phenotypes in polycythemia vera. N Engl J Med 371:808-17
Dickinson, Rachel E; Milne, Paul; Jardine, Laura et al. (2014) The evolution of cellular deficiency in GATA2 mutation. Blood 123:863-74
Rondelli, Damiano; Goldberg, Judith D; Isola, Luis et al. (2014) MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood 124:1183-91
Rheinemann, Lara; Seeger, Thalia S; Wehrle, Julius et al. (2014) NFE2 regulates transcription of multiple enzymes in the heme biosynthesis pathway. Haematologica 99:e208-10
Kapralova, Katarina; Lanikova, Lucie; Lorenzo, Felipe et al. (2014) RUNX1 and NF-E2 upregulation is not specific for MPNs, but is seen in polycythemic disorders with augmented HIF signaling. Blood 123:391-4
Wang, L; Swierczek, S I; Drummond, J et al. (2014) Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. Leukemia 28:935-8
Ye, Zhaohui; Liu, Cyndi F; Lanikova, Lucie et al. (2014) Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. Stem Cells 32:269-78
Essig, Aitomi; Duque-Afonso, Jesus; Schwemmers, Sven et al. (2014) The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cells. Leuk Res 38:340-5

Showing the most recent 10 out of 116 publications